A citation-based method for searching scientific literature

Thomas Kent, Deanne Gracias, Samuel Shepherd, David Clynes. Front Oncol 2020
Times Cited: 7







List of co-cited articles
33 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.
Marta Recagni, Joanna Bidzinska, Nadia Zaffaroni, Marco Folini. Cancers (Basel) 2020
9
42

Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
Xinjian Li, Xu Qian, Bin Wang, Yan Xia, Yanhua Zheng, Linyong Du, Daqian Xu, Dongming Xing, Ronald A DePinho, Zhimin Lu. Nat Cell Biol 2020
19
28

Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition.
Junbo Liang, Hong Zhao, Bill H Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang,[...]. Cancer Res 2020
11
28

Alternative lengthening of telomeres: models, mechanisms and implications.
Anthony J Cesare, Roger R Reddel. Nat Rev Genet 2010
541
28

Mutant ATRX: uncovering a new therapeutic target for glioma.
Santiago Haase, María Belén Garcia-Fabiani, Stephen Carney, David Altshuler, Felipe J Núñez, Flor M Méndez, Fernando Núñez, Pedro R Lowenstein, Maria G Castro. Expert Opin Ther Targets 2018
26
28

ALT: A Multi-Faceted Phenomenon.
Aurore Sommer, Nicola J Royle. Genes (Basel) 2020
3
66

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Hideyuki Arita, Yoshitaka Narita, Shintaro Fukushima, Kensuke Tateishi, Yuko Matsushita, Akihiko Yoshida, Yasuji Miyakita, Makoto Ohno, V Peter Collins, Nobutaka Kawahara,[...]. Acta Neuropathol 2013
216
28

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis.
Rita T Lawlor, Nicola Veronese, Antonio Pea, Alessia Nottegar, Lee Smith, Camilla Pilati, Jacopo Demurtas, Matteo Fassan, Liang Cheng, Claudio Luchini. BMC Cancer 2019
15
28

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors.
Aatur D Singhi, Ta-Chiang Liu, Justin L Roncaioli, Dengfeng Cao, Herbert J Zeh, Amer H Zureikat, Allan Tsung, J Wallis Marsh, Kenneth K Lee, Melissa E Hogg,[...]. Clin Cancer Res 2017
88
28

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.
Yuchen Jiao, Chanjuan Shi, Barish H Edil, Roeland F de Wilde, David S Klimstra, Anirban Maitra, Richard D Schulick, Laura H Tang, Christopher L Wolfgang, Michael A Choti,[...]. Science 2011
28

Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice.
H-C Jennifer Shen, Kris Ylaya, Klaus Pechhold, Arianne Wilson, Asha Adem, Stephen M Hewitt, Steven K Libutti. Endocrinology 2010
25
28

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chang S Chan, Saurabh V Laddha, Peter W Lewis, Matthew S Koletsky, Kenneth Robzyk, Edaise Da Silva, Paula J Torres, Brian R Untch, Janet Li, Promita Bose,[...]. Nat Commun 2018
50
28

Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.
Amit Tirosh, Sanjit Mukherjee, Justin Lack, Sudheer Kumar Gara, Sophie Wang, Martha M Quezado, Xavier M Keutgen, Xiaolin Wu, Maggie Cam, Suresh Kumar,[...]. Cancer 2019
16
28

The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit".
Ettore Luzi, Francesca Marini, Francesca Giusti, Gianna Galli, Loredana Cavalli, Maria Luisa Brandi. PLoS One 2012
58
28

Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1.
Philippe Bertolino, Wei-Min Tong, Dominique Galendo, Zhao-Qi Wang, Chang-Xian Zhang. Mol Endocrinol 2003
169
28

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
V Ramundo, M Del Prete, V Marotta, F Marciello, L Camera, V Napolitano, L De Luca, L Circelli, V Colantuoni, A Di Sarno,[...]. Clin Endocrinol (Oxf) 2014
21
28

Current and emerging therapies for PNETs in patients with or without MEN1.
Morten Frost, Kate E Lines, Rajesh V Thakker. Nat Rev Endocrinol 2018
23
28

Of mice and MEN1: Insulinomas in a conditional mouse knockout.
Judy S Crabtree, Peter C Scacheri, Jerrold M Ward, Sara R McNally, Gary P Swain, Cristina Montagna, Jeffrey H Hager, Douglas Hanahan, Helena Edlund, Mark A Magnuson,[...]. Mol Cell Biol 2003
166
28

Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Paloma Cejas, Yotam Drier, Koen M A Dreijerink, Lodewijk A A Brosens, Vikram Deshpande, Charles B Epstein, Elfi B Conemans, Folkert H M Morsink, Mindy K Graham, Gerlof D Valk,[...]. Nat Med 2019
46
28

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours.
H K Ahn, J Y Choi, K-M Kim, H Kim, S-H Choi, S H Park, J O Park, H Y Lim, W K Kang, J Lee,[...]. Br J Cancer 2013
55
28

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall,[...]. N Engl J Med 2014
812
28

Dynamic epigenetic regulation by menin during pancreatic islet tumor formation.
Wenchu Lin, Hideo Watanabe, Shouyong Peng, Joshua M Francis, Nathan Kaplan, Chandra Sekhar Pedamallu, Aruna Ramachandran, Agoston Agoston, Adam J Bass, Matthew Meyerson. Mol Cancer Res 2015
27
28

DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
E B Conemans, L Lodewijk, C B Moelans, G J A Offerhaus, C R C Pieterman, F H Morsink, O M Dekkers, W W de Herder, A R Hermus, A N van der Horst-Schrivers,[...]. Eur J Endocrinol 2018
12
28

The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors.
Jose Eduardo Nuñez, Mauro Donadio, Duilio Rocha Filho, Juliana Florinda Rego, Milton Barros, Maria Nirvana Formiga, Rossana Lopez, Rachel Riechelmann. J Gastrointest Oncol 2019
5
40

miR-24 regulates menin in the endocrine pancreas.
Jyothi Vijayaraghavan, Elaine C Maggi, Judy S Crabtree. Am J Physiol Endocrinol Metab 2014
29
28

Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1.
H-C Jennifer Shen, Mei He, Anathea Powell, Asha Adem, Dominique Lorang, Charles Heller, Amelia C Grover, Kris Ylaya, Stephen M Hewitt, Stephen J Marx,[...]. Cancer Res 2009
42
28

Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis.
Crystal D C Kamilaris, Constantine A Stratakis. Front Endocrinol (Lausanne) 2019
33
28

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond, Laetitia Dahan, Jean-Luc Raoul, Yung-Jue Bang, Ivan Borbath, Catherine Lombard-Bohas, Juan Valle, Peter Metrakos, Denis Smith, Aaron Vinik,[...]. N Engl J Med 2011
28

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.
K E Lines, M Stevenson, P Filippakopoulos, S Müller, H E Lockstone, B Wright, S Grozinsky-Glasberg, A B Grossman, S Knapp, D Buck,[...]. Oncogenesis 2017
20
28

Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias.
Francesco Tonelli, Geri Fratini, Gabriella Nesi, Maria Silvia Tommasi, Giacomo Batignani, Alberto Falchetti, Maria Luisa Brandi. Ann Surg 2006
81
28

Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group.
Elfi B Conemans, Lodewijk A A Brosens, Gabriela M Raicu-Ionita, Carolina R C Pieterman, Wouter W de Herder, Olaf M Dekkers, Ad R Hermus, Anouk N van der Horst-Schrivers, Peter H Bisschop, Bas Havekes,[...]. Pancreatology 2017
16
28

Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development.
Jieli Lu, Pedro L Herrera, Christine Carreira, Rémy Bonnavion, Christelle Seigne, Alain Calender, Philippe Bertolino, Chang Xian Zhang. Gastroenterology 2010
84
28

Epigenetic regulation by the menin pathway.
Zijie Feng, Jian Ma, Xianxin Hua. Endocr Relat Cancer 2017
16
28

ATRX represses alternative lengthening of telomeres.
Christine E Napier, Lily I Huschtscha, Adam Harvey, Kylie Bower, Jane R Noble, Eric A Hendrickson, Roger R Reddel. Oncotarget 2015
75
14

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Christian Hartmann, Jochen Meyer, Jörg Balss, David Capper, Wolf Mueller, Arne Christians, Jörg Felsberg, Marietta Wolter, Christian Mawrin, Wolfgang Wick,[...]. Acta Neuropathol 2009
759
14

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Jinquan Cai, Ping Zhu, Chuanbao Zhang, Qingbin Li, Zhiliang Wang, Guanzhang Li, Guangzhi Wang, Pei Yang, Jianlong Li, Bo Han,[...]. Oncotarget 2016
30
14


Targeting telomerase-expressing cancer cells.
Michel M Ouellette, Woodring E Wright, Jerry W Shay. J Cell Mol Med 2011
50
14

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Dan Rohle, Janeta Popovici-Muller, Nicolaos Palaskas, Sevin Turcan, Christian Grommes, Carl Campos, Jennifer Tsoi, Owen Clark, Barbara Oldrini, Evangelia Komisopoulou,[...]. Science 2013
727
14

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
420
14

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Akitake Mukasa, Shunsaku Takayanagi, Kuniaki Saito, Junji Shibahara, Yusuke Tabei, Kazuhide Furuya, Takafumi Ide, Yoshitaka Narita, Ryo Nishikawa, Keisuke Ueki,[...]. Cancer Sci 2012
65
14

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
Andrew Mancini, Ana Xavier-Magalhães, Wendy S Woods, Kien-Thiet Nguyen, Alexandra M Amen, Josie L Hayes, Christof Fellmann, Michael Gapinske, Andrew M McKinney, Chibo Hong,[...]. Cancer Cell 2018
40
14

Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.
Shigeo Ohba, Joydeep Mukherjee, Tor-Christian Johannessen, Andrew Mancini, Tracy T Chow, Matthew Wood, Lindsey Jones, Tali Mazor, Roxanne E Marshall, Pavithra Viswanath,[...]. Cancer Res 2016
27
14

Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Kenta Masui, Takashi Komori, Yukinari Kato, Kenkichi Masutomi, Koichi Ichimura, Satoshi Ogasawara, Mika K Kaneko, Hiroharu Oki, Hiroyoshi Suzuki, Masayuki Nitta,[...]. Biomed Res Int 2018
7
14

NuRD-ZNF827 recruitment to telomeres creates a molecular scaffold for homologous recombination.
Dimitri Conomos, Roger R Reddel, Hilda A Pickett. Nat Struct Mol Biol 2014
61
14

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
14

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, Kohei Fukuoka, Yuko Matsushita, Yoshiko Maida, Mami Yasukawa, Mitsuhiro Hayashi, Raku Shinkyo, Kiyomi Kikuchi,[...]. Cancer Sci 2019
15
14

IDH3α regulates one-carbon metabolism in glioblastoma.
Jasmine L May, Fotini M Kouri, Lisa A Hurley, Juan Liu, Serena Tommasini-Ghelfi, Yanrong Ji, Peng Gao, Andrea E Calvert, Andrew Lee, Navdeep S Chandel,[...]. Sci Adv 2019
15
14

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S Modrek, Dimitris G Placantonakis. Front Oncol 2019
75
14

Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Cemaliye B Akyerli, Şirin Yüksel, Özge Can, E Zeynep Erson-Omay, Yavuz Oktay, Erdal Coşgun, Ege Ülgen, Yiğit Erdemgil, Aydın Sav, Andreas von Deimling,[...]. J Neurosurg 2018
9
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.